Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.44 |
| ▸ | CTSL | P07711 | 8/20 | 0.44 |
| ▸ | CTSK | P43235 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827335 | 0.90 | CTSS (0.44) | CTSSCTSLCTSKMEN1KMT2A | |
| SCHEMBL4819482 | 0.89 | SMN1; SMN2 (0.41) | CTSSCTSKMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4818770 | 0.88 | GRM4 (0.38) | CTSSCTSKTSHRSMN1; SMN2 | |
| SCHEMBL4826952 | 0.87 | GRM4 (0.44) | CTSSCTSLCTSKSMN1; SMN2 | |
| SCHEMBL4826878 | 0.87 | TAAR1 (0.43) | CTSSCTSLCTSKTSHR | |
| SCHEMBL4824852 | 0.87 | TAAR1 (0.43) | CTSSCTSLCTSKTSHR | |
| SCHEMBL4819415 | 0.80 | NPSR1 (0.43) | CTSK | |
| SCHEMBL4824909 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL4820586 | 0.79 | CTSK (0.50) | CTSSCTSLCTSKSMN1; SMN2EPHX2 | |
| SCHEMBL4823780 | 0.79 | CTSK (0.50) | CTSSCTSLCTSKSMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | CTSS 2/4885CTSL 12/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.